Patents by Inventor Rene de Waal Malefyt

Rene de Waal Malefyt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Canine thymic stromal lymphopoietin protein and uses thereof to treat allergic symptoms
    Patent number: 8791242
    Abstract: The present invention discloses a canine TSLP protein and a nucleic acid that encodes that protein. Peptide fragments of the protein that comprise specific epitopes of the canine TSLP protein are also disclosed. The canine TSLP protein and related peptide fragments may be used as an antigen for immunological assays, as well as for vaccines that induce anti-TSLP antibodies. The present invention further discloses methods of making and using the canine TSLP gene, the canine TSLP protein, and the related peptide fragments.
    Type: Grant
    Filed: November 11, 2011
    Date of Patent: July 29, 2014
    Assignee: Intervet Inc.
    Inventors: Jeanine D. Mattson, Daniel M. Gorman, Rene de Waal Malefyt, Mohamad A. Morsey
  • MAMMALIAN CYTOKINES; RELATED REAGENTS
    Publication number: 20140170658
    Abstract: Purified genes encoding a cytokine or composite cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding these molecules are provided. Methods of using said reagents and diagnostic kits are also provided.
    Type: Application
    Filed: February 14, 2014
    Publication date: June 19, 2014
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: JACQUELINE C. TIMANS, STEFAN KARL-HEINZ PFLANZ, ROBERT A. KASTELEIN, J. FERNANDO BAZAN, DONNA RENNICK, RENE DE WAAL MALEFYT, JEANNE CHEUNG
  • ENGINEERED ANTI-TSLP ANTIBODY
    Publication number: 20140141011
    Abstract: The invention relates to binding compounds that specifically bind to human TSLP, as well as uses thereof, e.g., in the treatment of inflammatory disorders.
    Type: Application
    Filed: October 8, 2013
    Publication date: May 22, 2014
    Applicant: SCHERING CORPORATION
    Inventors: LEONARD G. PRESTA, RENE DE WAAL MALEFYT
  • Binding compounds for IL-27
    Patent number: 8691953
    Abstract: Purified genes encoding a cytokine or composite cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding these molecules are provided. Methods of using said reagents and diagnostic kits are also provided.
    Type: Grant
    Filed: December 20, 2011
    Date of Patent: April 8, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jacqueline C. Timans, Stefan Karl-Heinz Pflanz, Robert A. Kastelein, J. Fernando Bazan, Donna Rennick, Rene de Waal Malefyt, Jeanne Cheung
  • MAMMALIAN CYTOKINES; RECEPTORS; RELATED REAGENTS AND METHODS
    Publication number: 20140093875
    Abstract: Nucleic acids encoding mammalian cytokine receptor, e.g., for cytokine IL-B50, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.
    Type: Application
    Filed: December 2, 2013
    Publication date: April 3, 2014
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Pedro A. Reche-Gallardo, Vassili Soumelis, Yong-Jun Liu, Rene de Waal Malefyt, J. Fernando Bazan, Robert A. Kastelein
  • Engineered anti-TSLP antibody
    Patent number: 8580938
    Abstract: The invention relates to binding compounds that specifically bind to human TSLP, as well as uses thereof, e.g., in the treatment of inflammatory disorders.
    Type: Grant
    Filed: June 25, 2012
    Date of Patent: November 12, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Leonard G. Presta, Rene de Waal Malefyt
  • COMBINATION THERAPY FOR TREATMENT OF IMMUNE DISORDERS
    Publication number: 20130287775
    Abstract: Methods and compositions are provided for the treatment of immune disorders, such as autoimmune diseases, or cancers, involving combination therapy with agents that inhibit the development or maintenance of Th17 cells. Treatment regimens are provided in which an antagonist of a pro-inflammatory cytokine is administered for a time sufficient to alleviate signs and symptoms of an acute phase flare-up of the autoimmune disease, or cancer, and treatment with an antagonist of IL-23 is continued for a longer time to prevent recurrence of the acute event. Antagonists of PGE2 and CD161 are also disclosed for use in treatment of autoimmune, inflammatory and proliferative disorders.
    Type: Application
    Filed: June 24, 2013
    Publication date: October 31, 2013
    Inventors: Edward P. Bowman, Daniel J. Cua, Robert A. Kastelein, Kathy L. Miller, Melanie A. Kleinschek, Kristian S. Bak-Jensen, Katia Boniface, Brent S. McKenzie, Rene de Waal Malefyt
  • Engineered anti-TSLP antibody
    Patent number: 8512705
    Abstract: The invention relates to binding compounds that specifically bind to human TSLP, as well as uses thereof, e.g., in the treatment of inflammatory disorders.
    Type: Grant
    Filed: June 25, 2012
    Date of Patent: August 20, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Leonard G. Presta, Rene de Waal Malefyt
  • CANINE THYMIC STROMAL LYMPHOPOIETIN PROTEIN AND USES THEREOF
    Publication number: 20130183291
    Abstract: The present invention discloses a canine TSLP protein and a nucleic acid that encodes that protein. Peptide fragments of the protein that comprise specific epitopes of the canine TSLP protein are also disclosed. The canine TSLP protein and related peptide fragments may be used as an antigen for immunological assays, as well as for vaccines that induce anti-TSLP antibodies. The present invention further discloses methods of making and using the canine TSLP gene, the canine TSLP protein, and the related peptide fragments.
    Type: Application
    Filed: November 11, 2011
    Publication date: July 18, 2013
    Inventors: Jeanine D. Mattson, Daniel M. Gorman, Rene de Waal Malefyt, Mohamad A. Morsey
  • Engineered anti-TSLPR antibodies
    Patent number: 8475793
    Abstract: The invention relates to binding compounds that specifically bind to human TSLPR, as well as uses thereof, e.g., in the treatment of inflammatory disorders.
    Type: Grant
    Filed: February 6, 2009
    Date of Patent: July 2, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Rene De Waal Malefyt, Leonard G. Presta
  • ENGINEERED ANTI-TSLP ANTIBODY
    Publication number: 20130004508
    Abstract: The invention relates to binding compounds that specifically bind to human TSLP, as well as uses thereof, e.g., in the treatment of inflammatory disorders.
    Type: Application
    Filed: June 25, 2012
    Publication date: January 3, 2013
    Applicant: SCHERING CORPORATION
    Inventors: LEONARD G. PRESTA, RENE DE WAAL MALEFYT
  • ENGINEERED ANTI-TSLP ANTIBODY
    Publication number: 20130004503
    Abstract: The invention relates to binding compounds that specifically bind to human TSLP, as well as uses thereof, e.g., in the treatment of inflammatory disorders.
    Type: Application
    Filed: June 25, 2012
    Publication date: January 3, 2013
    Applicant: SCHERING CORPORATION
    Inventors: LEONARD G. PRESTA, RENE DE WAAL MALEFYT
  • USES OF MAMMALIAN CYTOKINE; RELATED REAGENTS
    Publication number: 20120225030
    Abstract: Provided are cytokines and methods of modulating activity of the immune system using cytokine agonists and antagonists. Also provided are methods of treatment of immune and proliferative disorders.
    Type: Application
    Filed: May 14, 2012
    Publication date: September 6, 2012
    Applicant: Schering Corporation
    Inventors: Rene de Waal Malefyt, Marilyn Travis, Elena Vaisberg
  • Engineered anti-TSLP antibody
    Patent number: 8232372
    Abstract: The invention relates to binding compounds that specifically bind to human TSLP, as well as uses thereof, e.g., in the treatment of inflammatory disorders.
    Type: Grant
    Filed: December 13, 2007
    Date of Patent: July 31, 2012
    Assignee: Schering Corp.
    Inventors: Leonard G. Presta, Rene de Waal Malefyt
  • METHODS OF TREATMENT USING AN ANTI IL B50 ANTIBODY
    Publication number: 20120177658
    Abstract: Nucleic acids encoding mammalian cytokine receptor, e.g., for cytokine IL-B50, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.
    Type: Application
    Filed: November 2, 2011
    Publication date: July 12, 2012
    Applicant: Schering Corp.
    Inventors: Pedro A. Reche-Gallardo, Vassilli Soumelis, Yong-Jun Liu, Rene de Waal Malefyt, J. Fernando Bazan, Robert A. Kastelein
  • Pathogenic TH17 Cells; related reagents and methods
    Publication number: 20120156699
    Abstract: Methods and compositions are provided for the treatment of immune disorders, such as autoimmune diseases, or cancers, involving combination therapy with agents that inhibit the development or maintenance of Th17 cells. Treatment regimens are provided in which an antagonist of a pro-inflammatory cytokine is administered for a time sufficient to alleviate signs and symptoms of an acute phase flare-up of the autoimmune disease, or cancer, and treatment with an antagonist of IL-23 is continued for a longer time to prevent recurrence of the acute event. Antagonists of PGE2 and CD161 are also disclosed for use in treatment of autoimmune, inflammatory and proliferative disorders.
    Type: Application
    Filed: February 24, 2012
    Publication date: June 21, 2012
    Applicant: Schering Corporation
    Inventors: Edward P. Bowman, Daniel J. Cua, Robert A. Kastelein, Kathy Lynn Miller, Melanie A. Kleinschek, Katia Boniface, Kristian S. Bak-Jensen, Brent S. McKenzie, Rene de Waal Malefyt
  • Use of IL-27 agonists to increase interferon-gamma production
    Patent number: 8178308
    Abstract: Provided are cytokines and methods of modulating activity of the immune system using cytokine agonists and antagonists. Also provided are methods of treatment of immune and proliferative disorders.
    Type: Grant
    Filed: May 18, 2007
    Date of Patent: May 15, 2012
    Assignee: Schering Corporation
    Inventors: Rene de Waal Malefyt, Marilyn Travis, Elena Vaisberg
  • MAMMALIAN CYTOKINES; RELATED REAGENTS
    Publication number: 20120115164
    Abstract: Purified genes encoding a cytokine or composite cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding these molecules are provided. Methods of using said reagents and diagnostic kits are also provided.
    Type: Application
    Filed: December 20, 2011
    Publication date: May 10, 2012
    Applicant: Schering Corporation
    Inventors: Jacqueline C. Timans, Stefan Karl-Heinz Pflanz, Robert A. Kastelein, J. Fernando Bazan, Donna Rennick, Rene de Waal Malefyt, Jeanne Cheung
  • IL-D80 polynucleotides
    Patent number: 8080392
    Abstract: Purified genes encoding a cytokine or composite cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding these molecules are provided. Methods of using said reagents and diagnostic kits are also provided.
    Type: Grant
    Filed: February 10, 2011
    Date of Patent: December 20, 2011
    Assignee: Schering Corporation
    Inventors: Jacqueline C. Timans, Stefan Karl-Heinz Pflanz, Robert A. Kastelein, J. Fernando Bazan, Donna Rennick, Rene de Waal Malefyt, Jeanne Cheung
  • Fusion proteins comprising canine thymic stromal lymphopoietin protein and uses thereof
    Patent number: 8076456
    Abstract: The present invention discloses a canine TSLP protein and a nucleic acid that encodes that protein. Peptide fragments of the protein that comprise specific epitopes of the canine TSLP protein are also disclosed. The canine TSLP protein and related peptide fragments may be used as an antigen for immunological assays, as well as for vaccines that induce anti-TSLP antibodies. The present invention further discloses methods of making and using the canine TSLP gene, the canine TSLP protein, and the related peptide fragments.
    Type: Grant
    Filed: March 10, 2010
    Date of Patent: December 13, 2011
    Assignee: Intervet Inc.
    Inventors: Jeanine D. Mattson, Daniel M. Gorman, Rene de Waal Malefyt, Mohamad A. Morsey